2022 January 24
1.
Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19. Shin RK, Repovic P, Berger JR.
Neurol Ther. 2022 Jan 23. doi: 10.1007/s40120-021-00321-9. Online ahead of print.
PMID: 35066816
2.
Inflammasome Signaling in the Aging Brain and Age-Related Neurodegenerative Diseases. Brahadeeswaran S, Sivagurunathan N, Calivarathan L.
Mol Neurobiol. 2022 Jan 23. doi: 10.1007/s12035-021-02683-5. Online ahead of print.
PMID: 35066762 Review.
3.
Disease-modifying treatments for multiple sclerosis have not affected the incidence of neoplasms in clinical trials over 3 decades: a meta-analysis with meta-regression. Papadopoulos D, Gklinos P, Psarros G, Drellia K, Delicha EM, Friede T, Mitsikostas DD, Nicholas RS.
J Neurol. 2022 Jan 23. doi: 10.1007/s00415-021-10932-9. Online ahead of print.
PMID: 35066607
4.
The importance of drug titration in the management of patients with epilepsy. Seiden LG, Connor GS.
Epilepsy Behav. 2022 Jan 20;128:108517. doi: 10.1016/j.yebeh.2021.108517. Online ahead of print.
PMID: 35066388 Review.
5.
Serum levels of lipocalin-2 are elevated at early times in African American relapsing remitting multiple sclerosis patients. Kalinin S, Boullerne AI, Feinstein DL.
J Neuroimmunol. 2022 Jan 12;364:577810. doi: 10.1016/j.jneuroim.2022.577810. Online ahead of print.
PMID: 35066333
6.
Pelvic floor muscle training on urinary incontinence and sexual function in people with multiple sclerosis: A systematic review. Yavas I, Emuk Y, Kahraman T.
Mult Scler Relat Disord. 2022 Jan 18;58:103538. doi: 10.1016/j.msard.2022.103538. Online ahead of print.
PMID: 35066277 Review.
7.
Remyelination trial failures: Repercussions of ignoring neurorehabilitation and exercise in repair. Ploughman M, Yong VW, Spermon B, Goelz S, Giovannoni G.
Mult Scler Relat Disord. 2022 Jan 19;58:103539. doi: 10.1016/j.msard.2022.103539. Online ahead of print.
PMID: 35066276 Review.
8.
Validity and reliability of the 3-meter backward walk test in mildly disabled persons with multiple sclerosis. Bilek F, Demir CF.
Mult Scler Relat Disord. 2022 Jan 19;58:103532. doi: 10.1016/j.msard.2022.103532. Online ahead of print.
PMID: 35066275
9.
It’s time to talk about disclosure and concealment in MS. Leavitt VM, Kever A.
Mult Scler Relat Disord. 2022 Jan 18;58:103537. doi: 10.1016/j.msard.2022.103537. Online ahead of print.
PMID: 35066274
10.
Gastrointestinal pathologic findings of teriflunomide associated diarrhea. Fan JH, Fogt F, Berger JR.
Mult Scler Relat Disord. 2022 Jan 10;58:103506. doi: 10.1016/j.msard.2022.103506. Online ahead of print.
PMID: 35066272
11.
Surviving a global pandemic: The experience of depression, anxiety, and loneliness among individuals with multiple sclerosis. Strober L, Weber E, Lequerica A, Chiaravalloti N.
Mult Scler Relat Disord. 2022 Jan 4;58:103497. doi: 10.1016/j.msard.2022.103497. Online ahead of print.
PMID: 35066271
12.
Consistency of the “central vein sign” in chronic multiple sclerosis lesions. Reichl M, Wittayer M, Weber CE, Platten M, Gass A, Eisele P.
Mult Scler Relat Disord. 2022 Jan 15;58:103530. doi: 10.1016/j.msard.2022.103530. Online ahead of print.
PMID: 35066270
13.
Myocardial infarction and stroke risks in multiple sclerosis patients: A two-sample Mendelian randomization study. Peng H, Wu X, Wen Y, Lin J, Guan W.
Mult Scler Relat Disord. 2022 Jan 6;58:103501. doi: 10.1016/j.msard.2022.103501. Online ahead of print.
PMID: 35066269
14.
Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Wood CH, Robertson NP, Htet ZM, Tallantyre EC.
Mult Scler Relat Disord. 2022 Jan 12;58:103492. doi: 10.1016/j.msard.2022.103492. Online ahead of print.
PMID: 35066268
15.
Glutathione targeted tragacanthic acid-chitosan as a non-viral vector for brain delivery of miRNA-219a-5P: An in vitro/in vivo study. Shamaeizadeh N, Varshosaz J, Mirian M, Aliomrani M.
Int J Biol Macromol. 2022 Jan 20:S0141-8130(22)00115-5. doi: 10.1016/j.ijbiomac.2022.01.100. Online ahead of print.
PMID: 35066026
16.
Reconnoitering the transformative journey of minocycline from an antibiotic to an antiepileptic drug. Singh T, Thapliyal S, Bhatia S, Singh V, Singh M, Singh H, Kumar A, Mishra A.
Life Sci. 2022 Jan 20:120346. doi: 10.1016/j.lfs.2022.120346. Online ahead of print.
PMID: 35065989 Review.
17.
A copper chaperone-mimetic polytherapy for SOD1-associated amyotrophic lateral sclerosis. McAlary L, Shephard VK, Wright GSA, Yerbury JJ.
J Biol Chem. 2022 Jan 20:101612. doi: 10.1016/j.jbc.2022.101612. Online ahead of print.
PMID: 35065969
2022 January 23
1.
The aerobic capacity – fatigue relationship in persons with Multiple Sclerosis is not reproducible in a pooled analysis of two randomized controlled trials. Wolf F, Rademacher A, Joisten N, Proschinger S, Schlagheck ML, Bloch W, Gonzenbach R, Kool J, Bansi J, Zimmer P.
Mult Scler Relat Disord. 2021 Dec 27;58:103476. doi: 10.1016/j.msard.2021.103476. Online ahead of print.
PMID: 35065407
2.
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Verschuuren JJ, Palace J, Murai H, Tannemaat MR, Kaminski HJ, Bril V.
Lancet Neurol. 2022 Feb;21(2):189-202. doi: 10.1016/S1474-4422(21)00463-4.
PMID: 35065041 Review.
3.
Activation of Annexin A2 signaling at the blood-brain barrier in a mouse model of multiple sclerosis. Tezuka K, Suzuki M, Sato R, Kawarada S, Terasaki T, Uchida Y.
J Neurochem. 2022 Jan 22. doi: 10.1111/jnc.15578. Online ahead of print.
PMID: 35064931
4.
A Principal Component Analysis Approach to Estimate the Disability Status for Patients with Multiple Sclerosis Using Japanese Claims Data. Kawachi I, Otaka H, Iwasaki K, Takeshima T, Ueda K.
Neurol Ther. 2022 Jan 22. doi: 10.1007/s40120-022-00324-0. Online ahead of print.
PMID: 35064908
5.
A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector. Farej R, Rametta M, La Rose A, Quillen A, McLeod K.
Neurol Ther. 2022 Jan 22. doi: 10.1007/s40120-022-00323-1. Online ahead of print.
PMID: 35064907
6.
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience. Rosa L, Scandurra C, Chiodi A, Petracca M, Costabile T, Lauro F, Moccia M, Carotenuto A, Maldonato NM, Brescia Morra V, Lanzillo R.
J Clin Psychol Med Settings. 2022 Jan 22. doi: 10.1007/s10880-022-09849-w. Online ahead of print.
PMID: 35064863
7.
Hemostasis components as therapeutic targets in autoimmune demyelination. Abbadessa G, Mainero C, Bonavita S.
Clin Pharmacol Ther. 2022 Jan 21. doi: 10.1002/cpt.2532. Online ahead of print.
PMID: 35064575 Review.
8.
Short inertial sensor-based gait tests reflect perceived state fatigue in multiple sclerosis. Ibrahim AA, Flachenecker F, Gaßner H, Rothammer V, Klucken J, Eskofier BM, Kluge F.
Mult Scler Relat Disord. 2022 Jan 14;58:103519. doi: 10.1016/j.msard.2022.103519. Online ahead of print.
PMID: 35063910
9.
Cognitive rehabilitation outcomes in patients with Multiple sclerosis: Preliminary data about the potential role of personality traits. Maggio MG, Stagnitti MC, Calatozzo P, Formica S, Latella D, Manuli A, Avena G, Oddo V, Calabrò RS.
Mult Scler Relat Disord. 2022 Jan 15;58:103533. doi: 10.1016/j.msard.2022.103533. Online ahead of print.
PMID: 35063908
10.
Role of interleukin-17 signaling pathway in the interaction between multiple sclerosis and acute myocardial infarction. Jain S.
Mult Scler Relat Disord. 2022 Jan 11;58:103515. doi: 10.1016/j.msard.2022.103515. Online ahead of print.
PMID: 35063907
11.
Atypical antipsychotics in multiple sclerosis: A review of their in vivo immunomodulatory effects. Stamoula Ε, Ainatzoglou A, Stamatellos V, Dardalas I, Siafis S, Matsas A, Stamoulas K, Papazisis G.
Mult Scler Relat Disord. 2022 Jan 12;58:103522. doi: 10.1016/j.msard.2022.103522. Online ahead of print.
PMID: 35063906 Review.
12.
Is there a multiple sclerosis personality? Personality characteristics in newly diagnosed multiple sclerosis and association with mood and cognition. Chu L, Casserly C, Rosehart H, Morrow SA.
J Neurol Sci. 2022 Jan 11;434:120145. doi: 10.1016/j.jns.2022.120145. Online ahead of print.
PMID: 35063812
13.
Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis. Nepal G, Kharel S, Coghlan MA, Rayamajhi P, Ojha R.
J Neuroimmunol. 2022 Jan 13;364:577812. doi: 10.1016/j.jneuroim.2022.577812. Online ahead of print.
PMID: 35063726 Review.
14.
Cordycepin prevents and ameliorates experimental autoimmune encephalomyelitis by inhibiting leukocyte infiltration and reducing neuroinflammation. Song YC, Liu CT, Lee HJ, Yen HR.
Biochem Pharmacol. 2022 Jan 18:114918. doi: 10.1016/j.bcp.2022.114918. Online ahead of print.
PMID: 35063441
15.
Physical activity and sedentary behavior timing in fatigued and non-fatigued adults with multiple sclerosis. Cederberg KLJ, Jeng B, Sasaki JE, Motl RW.
Arch Phys Med Rehabil. 2022 Jan 18:S0003-9993(22)00018-1. doi: 10.1016/j.apmr.2021.12.022. Online ahead of print.
PMID: 35063422
16.
The impact of lifetime coffee and tea loads on Multiple Sclerosis severity. Ivashynka A, Leone MA, Barizzone N, Cucovici A, Cantello R, Vecchio D, Zuccalà M, Pizzino A, Copetti M, D’Alfonso S, Fontana A.
Clin Nutr ESPEN. 2022 Feb;47:199-205. doi: 10.1016/j.clnesp.2021.12.014. Epub 2021 Dec 23.
PMID: 35063202
17.
The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Krasemann S, Haferkamp U, Pfefferle S, Woo MS, Heinrich F, Schweizer M, Appelt-Menzel A, Cubukova A, Barenberg J, Leu J, Hartmann K, Thies E, Littau JL, Sepulveda-Falla D, Zhang L, Ton K, Liang Y, Matschke J, Ricklefs F, Sauvigny T, Sperhake J, Fitzek A, Gerhartl A, Brachner A, Geiger N, König EM, Bodem J, Franzenburg S, Franke A, Moese S, Müller FJ, Geisslinger G, Claussen C, Kannt A, Zaliani A, Gribbon P, Ondruschka B, Neuhaus W, Friese MA, Glatzel M, Pless O.
Stem Cell Reports. 2022 Jan 3:S2213-6711(21)00650-0. doi: 10.1016/j.stemcr.2021.12.011. Online ahead of print.
PMID: 35063125
18.
Effect of dynamic neuromuscular stabilization on balance and trunk function in people with multiple sclerosis: protocol for a randomized control trial. Abadi Marand L, Noorizadeh Dehkordi S, Roohi-Azizi M, Dadgoo M.
Trials. 2022 Jan 21;23(1):69. doi: 10.1186/s13063-022-06015-3.
PMID: 35063011
19.
COVID-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran. Nabavi SM, Mehrabani M, Ghalichi L, Nahayati MA, Ghaffari M, Ashtari F, Mohammadianinejad SE, Karimi S, Faghani L, Yazdanbakhsh S, Najafian A, Shahpasand K, Vosough M.
Vaccines (Basel). 2022 Jan 17;10(1):135. doi: 10.3390/vaccines10010135.
PMID: 35062796
20.
Development Technologies for the Monitoring of Six-Minute Walk Test: A Systematic Review. Pires IM, Denysyuk HV, Villasana MV, Sá J, Marques DL, Morgado JF, Albuquerque C, Zdravevski E.
Sensors (Basel). 2022 Jan 12;22(2):581. doi: 10.3390/s22020581.
PMID: 35062542 Review.
21.
HERV-W Envelope Triggers Abnormal Dopaminergic Neuron Process through DRD2/PP2A/AKT1/GSK3 for Schizophrenia Risk. Yan Q, Wu X, Zhou P, Zhou Y, Li X, Liu Z, Tan H, Yao W, Xia Y, Zhu F.
Viruses. 2022 Jan 14;14(1):145. doi: 10.3390/v14010145.
PMID: 35062349
22.
Therapeutic promise of carotenoids as antioxidants and anti-inflammatory agents in neurodegenerative disorders. Kabir MT, Rahman MH, Shah M, Jamiruddin MR, Basak D, Al-Harrasi A, Bhatia S, Ashraf GM, Najda A, El-Kott AF, Mohamed HRH, Al-Malky HS, Germoush MO, Altyar AE, Alwafai EB, Ghaboura N, Abdel-Daim MM.
Biomed Pharmacother. 2022 Feb;146:112610. doi: 10.1016/j.biopha.2021.112610. Epub 2022 Jan 4.
PMID: 35062074 Review.
2022 January 22
1.
Local autoimmune encephalomyelitis model in a rat brain with precise control over lesion placement. Kalkowski L, Golubczyk D, Kwiatkowska J, Domzalska M, Walczak P, Malysz-Cymborska I.
PLoS One. 2022 Jan 21;17(1):e0262677. doi: 10.1371/journal.pone.0262677. eCollection 2022.
PMID: 35061807
2.
Assessing visually guided reaching in people with multiple sclerosis with and without self-reported upper limb impairment. Wijeyaratnam DO, Edwards T, Pilutti LA, Cressman EK.
PLoS One. 2022 Jan 21;17(1):e0262480. doi: 10.1371/journal.pone.0262480. eCollection 2022.
PMID: 35061785
3.
Effects of quarantine applied during the COVID-19 pandemic on mental health and quality of life in patients with multiple sclerosis and healthy controls. Koc ER, Demir AB, Topaloglu E, Turan OF, Ozkaya G.
Neurol Sci. 2022 Jan 21. doi: 10.1007/s10072-022-05901-7. Online ahead of print.
PMID: 35061136
4.
Application of the “risk of ambulatory disability” (RoAD) score in a “real-world” single-center multiple sclerosis cohort. Pistor M, Hammer H, Salmen A, Hoepner R, Friedli C.
CNS Neurosci Ther. 2022 Jan 21. doi: 10.1111/cns.13806. Online ahead of print.
PMID: 35060326
5.
Complementary and alternative therapies in multiple sclerosis: a systematic literature classification and analysis. Arji G, Rezaeizadeh H, Moghadasi AN, Sahraian MA, Karimi M, Alizadeh M.
Acta Neurol Belg. 2022 Jan 21. doi: 10.1007/s13760-021-01847-3. Online ahead of print.
PMID: 35060096 Review.
6.
The role of efferocytosis in neuro-degenerative diseases. Taheri F, Taghizadeh E, Navashenaq JG, Rezaee M, Gheibihayat SM.
Neurol Sci. 2022 Jan 21. doi: 10.1007/s10072-021-05835-6. Online ahead of print.
PMID: 35059903 Review.
7.
Employment, health visits, mental health, and mortality in parents with a chronically ill child: a Danish nationwide population-based cohort study. Boesen MS, Thygesen LC, Blinkenberg M, Born AP, Uldall P, Magyari M, Eriksson F.
Eur J Pediatr. 2022 Jan 21. doi: 10.1007/s00431-021-04334-2. Online ahead of print.
PMID: 35059826
8.
Cancellous bone-like tissue replacement from calcinosis in patients with systemic sclerosis with multiple external root resorption. Memida T, Matsuda S, Nakamoto T, Ouhara K, Kajiya M, Hirata S, Sugiyama E, Kakimoto N, Mizuno N.
Bone Rep. 2022 Jan 8;16:101165. doi: 10.1016/j.bonr.2021.101165. eCollection 2022 Jun.
PMID: 35059476 Free PMC article.
9.
18F-FDG-PET correlates of aging and disease course in ALS as revealed by distinct PVC approaches. Ferraro PM, Campi C, Miceli A, Rolla-Bigliani C, Bauckneht M, Gualco L, Piana M, Marini C, Castellan L, Morbelli S, Caponnetto C, Sambuceti G, Roccatagliata L.
Eur J Radiol Open. 2022 Jan 13;9:100394. doi: 10.1016/j.ejro.2022.100394. eCollection 2022.
PMID: 35059473 Free PMC article.
10.
Therapeutic Benefits of Short-Arm Human Centrifugation in Multiple Sclerosis-A New Approach. Kourtidou-Papadeli C, Frantzidis CA, Bakirtzis C, Petridou A, Gilou S, Karkala A, Machairas I, Kantouris N, Nday CM, Dermitzakis EV, Bakas E, Mougios V, Bamidis PD, Vernikos J.
Front Neurol. 2022 Jan 4;12:746832. doi: 10.3389/fneur.2021.746832. eCollection 2021.
PMID: 35058870 Free PMC article.
11.
Successful treatment with dimethyl fumarate in a child with relapsing-remitting multiple sclerosis. Saijo N, Abe Y, Oikawa Y, Okubo Y, Endo W, Numata-Uematsu Y, Takahashi T, Uematsu M.
Brain Dev. 2022 Jan 17:S0387-7604(21)00247-3. doi: 10.1016/j.braindev.2021.12.010. Online ahead of print.
PMID: 35058083
12.
Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. Jarius S, Pache F, Körtvelyessy P, Jelčić I, Stettner M, Franciotta D, Keller E, Neumann B, Ringelstein M, Senel M, Regeniter A, Kalantzis R, Willms JF, Berthele A, Busch M, Capobianco M, Eisele A, Reichen I, Dersch R, Rauer S, Sandner K, Ayzenberg I, Gross CC, Hegen H, Khalil M, Kleiter I, Lenhard T, Haas J, Aktas O, Angstwurm K, Kleinschnitz C, Lewerenz J, Tumani H, Paul F, Stangel M, Ruprecht K, Wildemann B; ; in cooperation with the German Society for Cerebrospinal Fluid Diagnostics and Clinical Neurochemistry.
J Neuroinflammation. 2022 Jan 20;19(1):19. doi: 10.1186/s12974-021-02339-0.
PMID: 35057809
13.
In Vitro Methodologies to Study the Role of Advanced Glycation End Products (AGEs) in Neurodegeneration. Chrysanthou M, Miro Estruch I, Rietjens IMCM, Wichers HJ, Hoppenbrouwers T.
Nutrients. 2022 Jan 15;14(2):363. doi: 10.3390/nu14020363.
PMID: 35057544 Review.
14.
Design of Oral Sustained-Release Pellets by Modeling and Simulation Approach to Improve Compliance for Repurposing Sobrerol. Lu CH, Huang YF, Chu IM.
Pharmaceutics. 2022 Jan 11;14(1):167. doi: 10.3390/pharmaceutics14010167.
PMID: 35057064
15.
Synthesis and Biological Investigation of Bile Acid-Paclitaxel Hybrids. Melloni E, Marchesi E, Preti L, Casciano F, Rimondi E, Romani A, Secchiero P, Navacchia ML, Perrone D.
Molecules. 2022 Jan 12;27(2):471. doi: 10.3390/molecules27020471.
PMID: 35056786
16.
The Relationship between Cognitive Dysfunction and Postural Stability in Multiple Sclerosis. Redlicka J, Zielińska-Nowak E, Lipert A, Miller E.
Medicina (Kaunas). 2021 Dec 21;58(1):6. doi: 10.3390/medicina58010006.
PMID: 35056313
17.
Advance Care Planning in Neurodegenerative Disorders: A Scoping Review. Giordano A, De Panfilis L, Perin M, Servidio L, Cascioli M, Grasso MG, Lugaresi A, Pucci E, Veronese S, Solari A.
Int J Environ Res Public Health. 2022 Jan 12;19(2):803. doi: 10.3390/ijerph19020803.
PMID: 35055625 Review.
18.
Escalation vs. Early Intense Therapy in Multiple Sclerosis. Casanova B, Quintanilla-Bordás C, Gascón F.
J Pers Med. 2022 Jan 17;12(1):119. doi: 10.3390/jpm12010119.
PMID: 35055434 Review.
19.
Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses. Ramo-Tello C, Blanco Y, Brieva L, Casanova B, Martínez-Cáceres E, Ontaneda D, Ramió-Torrentá L, Rovira À.
J Pers Med. 2021 Dec 22;12(1):6. doi: 10.3390/jpm12010006.
PMID: 35055321
20.
The Dual Role of the β2-Adrenoreceptor in the Modulation of IL-17 and IFN-γ Production by T Cells in Multiple Sclerosis. Melnikov M, Rogovskii V, Sviridova A, Lopatina A, Pashenkov M, Boyko A.
Int J Mol Sci. 2022 Jan 8;23(2):668. doi: 10.3390/ijms23020668.
PMID: 35054851
21.
Thrombotic Thrombocytopenic Purpura in Interferon Beta-1a-Treated Patient Diagnosed with Relapsing-Remitting Multiple Sclerosis: A Case Report. Plesa CF, Chitimus DM, Sirbu CA, Țânțu MM, Ghinescu MC, Anghel D, Ionita-Radu F.
Life (Basel). 2022 Jan 7;12(1):80. doi: 10.3390/life12010080.
PMID: 35054473
22.
Clinical Predictors of Neurogenic Lower Urinary Tract Dysfunction in Persons with Multiple Sclerosis. Beck J, Jaekel AK, Zeller FL, Kowollik M, Kurze I, Kaufmann A, Feneberg W, Brandt A, Flachenecker P, Henze T, Domurath B, Schmidt P, Vance WN, Goldschmidt F, Kirschner-Hermanns RKM, Knüpfer SC.
Diagnostics (Basel). 2022 Jan 13;12(1):191. doi: 10.3390/diagnostics12010191.
PMID: 35054358
23.
Serum Vitamin D as a Biomarker in Autoimmune, Psychiatric and Neurodegenerative Diseases. Bivona G, Gambino CM, Lo Sasso B, Scazzone C, Giglio RV, Agnello L, Ciaccio M.
Diagnostics (Basel). 2022 Jan 6;12(1):130. doi: 10.3390/diagnostics12010130.
PMID: 35054296 Review.
24.
Information Processing Speed Assessed with Letter Digit Substitution Test in Croatian Sample of Multiple Sclerosis Patients. Jerković A, Matijaca M, Proroković A, Šikić A, Košta V, Ćurković Katić A, Dolić K, Duka Glavor K, Šoda J, Đogaš Z, Rogić Vidaković M.
Diagnostics (Basel). 2022 Jan 4;12(1):111. doi: 10.3390/diagnostics12010111.
PMID: 35054278
25.
A Comparison of Magnetic Resonance Imaging Methods to Assess Multiple Sclerosis Lesions: Implications for Patient Characterization and Clinical Trial Design. Haacke EM, Bernitsas E, Subramanian K, Utriainen D, Palutla VK, Yerramsetty K, Kumar P, Sethi SK, Chen Y, Latif Z, Jella P, Gharabaghi S, Wang Y, Zhang X, Comley RA, Beaver J, Luo Y.
Diagnostics (Basel). 2021 Dec 30;12(1):77. doi: 10.3390/diagnostics12010077.
PMID: 35054244
26.
“What Is Hidden behind the Mask?” Facial Emotion Recognition at the Time of COVID-19 Pandemic in Cognitively Normal Multiple Sclerosis Patients. Ziccardi S, Crescenzo F, Calabrese M.
Diagnostics (Basel). 2021 Dec 27;12(1):47. doi: 10.3390/diagnostics12010047.
PMID: 35054216
27.
Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment. Prezioso C, Ciotti M, Brazzini G, Piacentini F, Passerini S, Grimaldi A, Landi D, Nicoletti CG, Zingaropoli MA, Iannetta M, Altieri M, Conte A, Limongi D, Marfia GA, Ciardi MR, Mastroianni CM, Palamara AT, Moens U, Pietropaolo V.
J Clin Med. 2022 Jan 11;11(2):347. doi: 10.3390/jcm11020347.
PMID: 35054041
28.
A Comparison of IgG Index and Oligoclonal Band in the Cerebrospinal Fluid for Differentiating between RRMS and NMOSD. Chen B, Tian DS, Bu BT.
Brain Sci. 2021 Dec 31;12(1):69. doi: 10.3390/brainsci12010069.
PMID: 35053810
29.
Split-Belt Training but Not Cerebellar Anodal tDCS Improves Stability Control and Reduces Risk of Fall in Patients with Multiple Sclerosis. Nguemeni C, Hiew S, Kögler S, Homola GA, Volkmann J, Zeller D.
Brain Sci. 2021 Dec 31;12(1):63. doi: 10.3390/brainsci12010063.
PMID: 35053807
30.
Cognitive Rehabilitation in Multiple Sclerosis in the Period from 2013 and 2021: A Narrative Review. Brochet B.
Brain Sci. 2021 Dec 30;12(1):55. doi: 10.3390/brainsci12010055.
PMID: 35053798 Review.
31.
Digital Innovation in Multiple Sclerosis Management. Ziemssen T, Haase R.
Brain Sci. 2021 Dec 29;12(1):40. doi: 10.3390/brainsci12010040.
PMID: 35053784
32.
Paediatric Multiple Sclerosis: A Scoping Review of Patients’ and Parents’ Perspectives. Luca M, Ortega-Castro N, Patti F.
Children (Basel). 2021 Dec 25;9(1):11. doi: 10.3390/children9010011.
PMID: 35053636 Review.
33.
TDP-43 Cytoplasmic Translocation in the Skin Fibroblasts of ALS Patients. Rubio MA, Herrando-Grabulosa M, Velasco R, Blasco I, Povedano M, Navarro X.
Cells. 2022 Jan 8;11(2):209. doi: 10.3390/cells11020209.
PMID: 35053327
34.
Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives. Rahman MM, Islam MR, Islam MT, Harun-Or-Rashid M, Islam M, Abdullah S, Uddin MB, Das S, Rahaman MS, Ahmed M, Alhumaydhi FA, Emran TB, Mohamed AA, Faruque MRI, Khandaker MU, Mostafa-Hedeab G.
Biology (Basel). 2022 Jan 17;11(1):147. doi: 10.3390/biology11010147.
PMID: 35053145 Review.
35.
Therapeutic Strategies Targeting Mitochondrial Calcium Signaling: A New Hope for Neurological Diseases? Rodríguez LR, Lapeña-Luzón T, Benetó N, Beltran-Beltran V, Pallardó FV, Gonzalez-Cabo P, Navarro JA.
Antioxidants (Basel). 2022 Jan 15;11(1):165. doi: 10.3390/antiox11010165.
PMID: 35052668 Review.
36.
Vitamin B12 Reduces TDP-43 Toxicity by Alleviating Oxidative Stress and Mitochondrial Dysfunction. Jeon YM, Kwon Y, Lee S, Kim S, Jo M, Lee S, Kim SR, Kim K, Kim HJ.
Antioxidants (Basel). 2021 Dec 29;11(1):82. doi: 10.3390/antiox11010082.
PMID: 35052586
37.
Coenzyme Q10, Ageing and the Nervous System: An Overview. Mantle D, Heaton RA, Hargreaves IP.
Antioxidants (Basel). 2021 Dec 21;11(1):2. doi: 10.3390/antiox11010002.
PMID: 35052506 Review.
38.
Capturing SNP Association across the NK Receptor and HLA Gene Regions in Multiple Sclerosis by Targeted Penalised Regression Models. Burnard SM, Lea RA, Benton M, Eccles D, Kennedy DW, Lechner-Scott J, Scott RJ.
Genes (Basel). 2021 Dec 29;13(1):87. doi: 10.3390/genes13010087.
PMID: 35052430
2022 January 19
1.
The Heimann-Bielschowsky phenomenon after optic neuritis. Anagnostou E, Karathanasis D, Evangelopoulos ME.
Mult Scler Relat Disord. 2022 Jan 11;58:103523. doi: 10.1016/j.msard.2022.103523. Online ahead of print.
PMID: 35042093
2.
Impact of rituximab in Mexican patients with Multiple Sclerosis-A single-center retrospective study. Bribiesca-Contreras E, García-Estrada C, Gómez-Figueroa E, Zertuche-Ortuño L, Rodríguez-Rivas R, Marcín-Sierra M, Delgado-Niño M, Rivas-Alonso V, Corona-Vázquez T, Flores-Rivera J.
Mult Scler Relat Disord. 2022 Jan 4;58:103485. doi: 10.1016/j.msard.2021.103485. Online ahead of print.
PMID: 35042092
3.
Deep brain stimulation use in treating multiple sclerosis tremor: A practical approach for meta-analyses. Serhan A, Kiwan A, Abushukair H, Yassin A.
Mult Scler Relat Disord. 2022 Jan 2;58:103491. doi: 10.1016/j.msard.2022.103491. Online ahead of print.
PMID: 35042091
4.
Cost of Illness of Multiple Sclerosis in Isfahan, Iran, From a Social Perspective: A Comparison of the Human-Capital and Friction-Cost Methods. Amirsadri M, Rahimi F, Khajepour A.
Value Health Reg Issues. 2022 Jan 15;30:26-30. doi: 10.1016/j.vhri.2021.10.006. Online ahead of print.
PMID: 35042020
5.
Metabolomics as a promising tool for improving understanding of Multiple Sclerosis: a review of recent advances. Liu Z, Jeffrey W, Rui B.
Biomed J. 2022 Jan 15:S2319-4170(22)00004-X. doi: 10.1016/j.bj.2022.01.004. Online ahead of print.
PMID: 35042018 Review.
6.
Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors. Ma B, Metrick CM, Gu C, Hoemberger M, Bajrami B, Bame E, Huang J, Mingueneau M, Murugan P, Santoro JC, Tang H, Wang T, Hopkins BT.
Bioorg Med Chem Lett. 2022 Jan 15:128549. doi: 10.1016/j.bmcl.2022.128549. Online ahead of print.
PMID: 35041943
7.
Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple Sclerosis. Kuchimanchi M, Bockbrader H, Dolphin N, Epling D, Quinlan L, Chapel S, Penner N.
Neurol Ther. 2022 Jan 18. doi: 10.1007/s40120-021-00316-6. Online ahead of print.
PMID: 35041178
8.
Ictal onset stereoelectroencephalography patterns in temporal lobe epilepsy: type, distribution, and prognostic value. Cui D, Gao R, Xu C, Yan H, Zhang X, Yu T, Zhang G.
Acta Neurochir (Wien). 2022 Jan 18. doi: 10.1007/s00701-022-05122-z. Online ahead of print.
PMID: 35041086
9.
Potentially modifiable associates of anxiety in people with multiple sclerosis: a systematic review. Fahy A, Maguire R.
Disabil Rehabil. 2022 Jan 18:1-12. doi: 10.1080/09638288.2021.2022776. Online ahead of print.
PMID: 35040719
10.
Progranulin as a therapeutic target in neurodegenerative diseases. Rhinn H, Tatton N, McCaughey S, Kurnellas M, Rosenthal A.
Trends Pharmacol Sci. 2022 Jan 15:S0165-6147(21)00232-7. doi: 10.1016/j.tips.2021.11.015. Online ahead of print.
PMID: 35039149 Review.
11.
[Clinical-etiological and MRI parallels of encephalitis in children]. Skripchenko EY, Ivanova GP, Skripchenko NV, Astapova AV, Gorelik EY, Vilnitz AA, Marchenko NV.
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(11. Vyp. 2):86-94. doi: 10.17116/jnevro202112111286.
PMID: 35038852 Russian.
12.
SARS-CoV-2 memory B and T cell profiles in mild COVID-19 convalescent patients. Gurevich M, Zilkha-Falb R, Sonis P, Magalashvili D, Menascu S, Flechter S, Dolev M, Mandel M, Achiron A.
Int J Infect Dis. 2022 Feb;115:208-214. doi: 10.1016/j.ijid.2021.12.309. Epub 2021 Dec 8.
PMID: 34896265 Free PMC article.
13.
BRIE2: computational identification of splicing phenotypes from single-cell transcriptomic experiments. Huang Y, Sanguinetti G.
Genome Biol. 2021 Aug 27;22(1):251. doi: 10.1186/s13059-021-02461-5.
PMID: 34452629 Free PMC article.
14.
No strong HLA association with MOG antibody disease in the UK population. Grant-Peters M, Passos GRD, Yeung HY, Jacob A, Huda S, Leite MI, Dendrou CA, Palace J.
Ann Clin Transl Neurol. 2021 Jul;8(7):1502-1507. doi: 10.1002/acn3.51378. Epub 2021 May 15.
PMID: 33991459 Free PMC article.